Prospective, single-centre, randomized, controlled, open-label, evaluator-blinded, superiority trial.
The primary objective is to establish whether ESP ropivacaine reduces post-operative opioid use and improves pain rating post-operatively. The secondary objectives include adverse event incidence, time to ambulation and time to discharge.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
50
Local anesthetic for injection
Bandage will be placed in the presumed injection site while patients in under general anesthesia
National Center for Oncology
Astana, Kazakhstan
Mean cumulative opioid consumption up to 24 hours after surgery
Cumulative opioid consumption will be recorded for 24 hours following surgery
Time frame: 24 hours post-operation
Post-operative pain score
Numerical rating scale (0= no pain; 10= worst pain imaginable) will be used
Time frame: Measured post-operatively at 0, 2, 4, 6, 8, 10, 12, 16, 20, 24 hours after surgery.
Time to ambulation
The time that the patient is able to walk independently, after surgery
Time frame: Between surgery and discharge from hospital, expected time is between 1 day to 1 week
Time to discharge
From time of surgery completion to discharge from hospital
Time frame: Expected time to discharge is up to 2 weeks
Usage of NSAIDs post surgery
Dose
Time frame: Total dose used during the 24 hour period after surgery.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.